ASCO 2022

CDK4/6i switch: who benefits from switching the CDK4/6…

Paradigm shift in breast cancer: Where do we use the…

What are the cosenquences of the new OS data for CDK4/6…

More data needed: Are the results clinical meaningful?…

What clincial value has statistical signifcance? How…

ADCs & CDK4/6i - paradigm shifts and therapy switches…

Patients perspectives: ADCs - how do manage the new,…

Determining HER2 receptor expression: How do we target…

Improvment of PFS & OS with activated alteration…

Oligometastasis: no advantage of additional…

T-DxD should be the new SoC for Her2low MBC patients

Disappoiting final OS data and its implications for our…

Discontiunation of trial is disappointing despite…

New SoC for large subpopulation of breast cancer…

Breakthrough news with antibody drug conjugate

SG is a new therapy option for HR+/HER2- MBC patients

Impressive and practice changing data of ADCs mark the…

ADC: future therapeutic option in advanced HR+/HER2 BC

Additional administration of ribociclib improves PFS…

SG may be a good option for pre-treated HR+/Her2- pts

First evidence on benefit of CDK4/6 inhibitors beyond…

Practice changing data

New agents for the clincial practice

Good therapeutic option in HR+ HER2- mBC after failure…

Exciting and practice changing news for HR+/Her2low MBC…

Revolution in the field of HR+ disease

Fascinating data of ADCs in breast cancer at ASCO22

Benefit of CDK4/6 Switch after Progression

Possible explanations of the negative study

New standard of care for HR+/Her2low patients

Combination of ctDNA and TKa assesment may improve…

No changes in clinical practice after new CDK4/6i-data

My ASCO22 highlights in metastatic breast cancer

Palbociclib - Overall survival data

No effect for local treatment of metastasis

Patritumab Deruxtecan: HER3-targeted ADC in HER3…

Endocrine therapy alone is important in treatment of…

Smart chemotherapy improves PFS

Exciting advances across a wide subset of breast…

Sacituzumab govitecan improves PCr in patients with…

Option for overcoming endocrine resistance?

Gamechanger in breast cancer

Una rivoluzione per il tumore mammario…

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

ADCs en cáncer de mama con receptores hormonales…

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…

SG come nuova opzione di cura per le pazienti con…

Les nouvelles données impressionnantes des ADC à l’ASCO…

Il sacituzumab govitecan migliora il PFS nei tumori…

La valutazione combinata di ctDNA e TKa può aiutare a…

I nuovi impressionanti risultati degli ADC a l’ASCO…

Novità entusiasmanti e practice changing per le…

Noutăți inovatoare cu conjugatul de medicamente cu…

Long term overall survival benefit of Denosumab in…

Adding towards deescalation in luminal A EBC by…

CT benefit for elderly patients, if they are able to…

Neoadjuvant Pembro decreased RCB. SG - first promising…

High concordance of local, central IHC and RT-PCR for…

My ASCO22 highlights in early breast cancer

Immunotherapy - Part 2

Molecular landscape - Part 2

Immunotherapy - Part 1

New components and therapies for advanced NSCLC

CLN-081 is a promising new agent for EGFR exon 20…

New treatment options for METexon 14 skipping:…

New option in patients harboring METex14 mutation

Bispecific Antibodies - the cMET field is moving

Role of IO and chemo-IO in patients with PD-L1 > 50%

Multiple aquired resistance mutations may drive disease…

Amivantamab as a future option for METex14 patients?

Promising results for pre-treated patients with…

Is adagrasib an alternative to sotorasib?

Strategies for PD-L1 > 50%

CLN-081 for patients with metastatic NSCLC and an…

PD-L1 over 50%: Chemo-IO or IO?

A chemo-free option in patients with EGFR-mutation

KRASG12C mutation: Adagrasib is comparabale to…

Options after progression to chemo/IO and for KRASG12C…

In the second line: Options for Immunotherapy…

Was tun nach Versagen einer Chemoimmun-Therapie?

Bispezifische Antikörper - Neues von CHRYSALIS

Une nouvelle option, l’amivantamab, en situation de…

PD-L1 über 50 % - was tun?

L’adagrasib, inhibiteur de la mutation KRASG12C: une…

Veelbelovende resultaten voor voorbehandelde patienten…

Segunda Linea: opciones tras resistencia a…

Nuevas terapias para el CPCNP avanzado

CLN-081 voor patienten met gemetastaseerd NSCLC en een…

Nieuwe behandelopties voor METexon 14 skipping:…

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…

Neoadjuvant and adjuvant therapy - Part 2

Perspectives on multimodality

New treatment approaches in Stage III

CheckMate-816: Neoadjuvant therapy

NADIM-II strengthens the findings from CheckMate-816

Neue Ansätze im Stadium III

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…

No benefit for tiragolumab / novel anti-PD-1 mAB…

SKYSCRAPER-02: Subgroups could be important

PARP inhibitors in mCRPC: Do we need more genetic…

mCRPC: LuPSMA - new treatment option in mCRPC

ADT alone is no longer standard of care

Value of triple-therapy - complimentary study to…

PFS good surrogate endpoint for overall survival

LuPSMA & cabazitaxel are better than SoC alone

Lu-PSMA in the third line

Lu-PSMA effective regardless of prior or concomitant…

SUV mean at PET images as a prognostic tool for PSMA…

Frequent imaging for early detection of metastases in…

GGT impacts PCa patients care

Further updates from the VISION trial

TheraP shows no difference in overall survival between…

SUVmean is highly predictive of better PFS and OS

The highlights in GU cancers of ASCO22

Phase 1 study on combining LuPSMA treatment with…

Arbiraterone + Olaparib: Is it synergistic?

The efficacy of doublets in mHSPC

No big scoop, but encouraging results

SHR3680 - do we need a new androgen receptor inhibitor

3 year overall survival of TheraP study

Ongoing trial invetiagting the impact of…

Treårs överlevnadsresultat i TheraP studien.

Kvantifiering av PMSA PET upptaget som prognostisk…

Tidigare endpoints I mHSPC studier

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…

Lo mas destacado en tumores GU en ASCO 2022

EVEREST: Inisghts from the negative trial

Combination Therapy is State of the Art in Metastatic…

The relevance of quality of life in kidney cancer!

Should Everolimus be revisited for high-risk patients?

Should we be looking at Everolimus in the future?

Clear evidence for durable benefit for patients with…

Depth of remission in firstline

PSMA-PET may improve imaging of clear cell RCC

Belzutifann shows good tumor activity in renal cancer

Importance of health related quality of life

QoL & DepOR correlate with clinical outcomes - reminder…

Combi Axi + Pembro also successful with good risk…

Lo mas destacado en tumores GU en ASCO 2022

ADCs: do we enter a new era of therapy for urothelial…

New data on TKi utilization in bladder cancer

My highlights in localized urothelial cancer

The highlights in GU cancers of ASCO22

My highlights of metastasized urothelial cancer

The end of of VEGF-targeted therapy in urothelial…

ADCs: News from ASCO 2022

Investigating sasanlimab in BCG-unresponsive NMIBC

No big scoop, but encouraging results

Perioperative immuno-chemotherapy in MIBC

Exciting future for ADCs

Maintenance concepts

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το…

Few testicular tumors after 5 years

Precision oncology - NTRK worth to search the patients

Opportunities & challenges of cancer genetics

News from Sarcoma

Systemic therapy